Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe
Introduction: The incidence and mortality rates of kidney cancer in the Central and Eastern European (CEE) region are among the highest in the world. Access to second and subsequent lines of metastatic renal cell carcinoma (mRCC) therapies is highly varied in the region. Despite the increasing body...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2016
|
| Sorozat: | EXPERT OPINION ON PHARMACOTHERAPY
17 No. 1 |
| doi: | 10.1517/14656566.2016.1107043 |
| mtmt: | 2978013 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/16830 |
| LEADER | 02247nab a2200265 i 4500 | ||
|---|---|---|---|
| 001 | publ16830 | ||
| 005 | 20190924113100.0 | ||
| 008 | 190924s2016 hu o 0|| zxx d | ||
| 022 | |a 1465-6566 | ||
| 024 | 7 | |a 10.1517/14656566.2016.1107043 |2 doi | |
| 024 | 7 | |a 2978013 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Vrdoljak Eduard | |
| 245 | 1 | 0 | |a Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe |h [elektronikus dokumentum] / |c Vrdoljak Eduard |
| 260 | |c 2016 | ||
| 300 | |a 93-104 | ||
| 490 | 0 | |a EXPERT OPINION ON PHARMACOTHERAPY |v 17 No. 1 | |
| 520 | 3 | |a Introduction: The incidence and mortality rates of kidney cancer in the Central and Eastern European (CEE) region are among the highest in the world. Access to second and subsequent lines of metastatic renal cell carcinoma (mRCC) therapies is highly varied in the region. Despite the increasing body of evidence supporting the clinical benefit of multiple lines of treatment, access to treatment beyond first line is restricted in many of these countries.Areas covered: The adoption of targeted therapies for the first-line treatment of mRCC in the region was slow and faced many obstacles. In order to evaluate the current status of treatment beyond the first-line setting in the CEE region, this review examines the availability and reimbursement of mRCC drugs and clinical practice in institutions that treat patients with mRCC.Expert opinion: This review highlights the need to raise awareness among physicians, payers and regulators on clinical trial and cost-effectiveness data regarding the treatment of mRCC beyond the first line. The obstacles to mRCC drug access highlighted in this review need to be overcome to ensure that patients are receiving the best treatment available. | |
| 700 | 0 | 1 | |a Torday László |e aut |
| 700 | 0 | 1 | |a Szczylik Cezary |e aut |
| 700 | 0 | 1 | |a Kharkevich Galina I. |e aut |
| 700 | 0 | 1 | |a Bavbek Sevil E. |e aut |
| 700 | 0 | 1 | |a Sella Avishay |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/16830/1/PharmacoeconomicandclinicalimplicationsofsequentialtherapyformetastaticrenalcellcarcinomapatientsinCentralandEasternEurope.pdf |z Dokumentum-elérés |